GENESIS-PHARMA
12.1.2024 12:37:29 CET | Business Wire | Press release
GENESIS Pharma, a leading regional biopharma company operating in Europe, and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announce an exclusive distribution agreement for RIPRETINIB in 14 European markets in Central and Eastern Europe. Under the terms of the agreement, GENESIS Pharma will exclusively commercialize RIPRETINIB for the treatment of fourth-line gastrointestinal stromal tumor (GIST) in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia.
RIPRETINIB is approved in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Ms. Margarida Duarte, Senior Vice President, Head of International, Deciphera Pharmaceuticals stated: “We are excited to partner with GENESIS Pharma to distribute RIPRETINIB across Central and Eastern Europe, ensuring fourth-line GIST patients in these countries have access to this standard-of-care treatment. Deciphera is committed to commercializing RIPRETINIB globally, and our agreement with GENESIS Pharma builds upon the significant progress we have already made launching the therapy in Europe, positioning us well for continued growth as we work together to improve the lives of GIST patients”.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “We are pleased to expand the network of our international partners and honored that Deciphera recognized our expertise and track record in the commercialization of innovative biopharmaceutical products targeting severe and rare diseases. This agreement is an important step forward in expanding our geographical reach and delivering our mission to ensure that such products are made available to patients in the countries we operate. We look forward to joining forces with Deciphera to enable access to this important innovative therapy for eligible patients in Central and Eastern Europe”.
About Gastrointestinal stromal tumor (GIST)
Gastrointestinal stromal tumor (GIST) is a rare neoplasm of the gastrointestinal tract affecting the digestive tract or nearby structures within the abdomen, most often presenting in the stomach or small intestine1. GIST is the most frequent sarcoma of the gastrointestinal tract, with a reported incidence of 10-15 cases per million per year2. The majority of GISTs are driven by two oncogenic protein kinases, KIT and PDGFRA gain-of-function mutations. The most common primary mutations are in KIT kinase, representing approximately 80% of cases, or in PDGFRA kinase, representing approximately 5-10% of cases3. Current therapies are unable to inhibit the full spectrum of primary and secondary mutations, which drives resistance to most tyrosine kinase inhibitors (TKIs) therefore leading to disease progression4. Estimates for 5-year survival rate range from 48% to 90%, depending on the stage of the disease at diagnosis5.
About Deciphera
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, RIPRETINIB is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. RIPRETINIB is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
About GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharmagroup.com.
1. Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019 Feb;10(1):144-154.
2. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016 Feb;40:39-46.
3. Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498.
4. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7.
5. American Cancer Society. (March 1, 2023). Gastrointestinal stromal tumor survival rates. Retrieved December 21, 2023, from https://www.cancer.org/cancer/types/gastrointestinal-stromal-tumor/detection-diagnosis-staging/survival-rates.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111379909/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kraken Goes Live on Trever to Bring Full-Service Prime Brokerage to European Financial Institutions30.6.2026 10:30:00 CEST | Press release
European banks, brokers and other licensed financial institutions using Trever can now access Kraken Prime’s institutional crypto trading and qualified custody Kraken Prime, the full-service prime brokerage offering trading, qualified custody and other financial services through an integrated platform, is now available through Trever, the operating standard in digital asset banking. Trever’s Digital Asset Operating System is used by financial institutions across Europe to manage the full digital asset lifecycle within a single environment – including trading, treasury, settlement and bookkeeping. From today, banks and brokers using Trever can route execution, settle into qualified custody, record all transactions and access other services through Kraken Prime without leaving their existing operational environment. The integration extends Trever’s connectivity, bringing a prime brokerage relationship into the existing workflows institutional teams use across their digital asset operatio
Microsoft Takes Sisvel Wi-Fi Multimode Patent Pool Licence30.6.2026 10:17:00 CEST | Press release
Microsoft has become a licensee of the Sisvel Wi-Fi Multimode pool. The US computer and software giant is the latest in a string of major companies to take a licence to the standard essential patents offered through the programme. In doing so, it joins ASUS, Hewlett Packard Enterprise and Sony Group Corporation, as well as Huawei, Panasonic, Philips and ZTE which are also pool licensors alongside KPN, Mitsubishi Electric, Orange, Aegis 11 (a Sisvel affiliate), SK Telecom and Wilus. The Sisvel Wi-Fi Multimode pool covers both Wi-Fi 6 and Wi-Fi 7 and offers an efficient way to access essential Wi-Fi rights for years to come. It was publicly launched in January 2026 as the successor to the Sisvel Wi-Fi 6 patent pool. Over a three-year period under that programme, agreements were closed with 40 companies, including Acer, Netgear, Cisco and HP. “It is a pleasure to welcome Microsoft as a licensee of the Sisvel Wi-Fi Multimode pool,” says Alex Debski, Director of Licensing and Counsel Legal
STOKR Secures CASP and PI Licences in Luxembourg Ahead of MiCAR Deadline30.6.2026 10:00:00 CEST | Press release
Authorised by the CSSF just before the 1 July 2026 enforcement deadline, STOKR joins a small group of crypto-asset firms cleared to operate across the EU under a single, harmonised regime. STOKR, the Luxembourg-based digital securities platform, has received authorisation from the Commission de Surveillance du Secteur Financier (CSSF) under the EU's Markets in Crypto-Assets Regulation (MiCAR) and the Law of 10 November 2009 on payment services, securing its Crypto-Asset Service Provider (CASP) and Payment Institution (PI) licences just over a week before MiCAR's 1 July 2026 enforcement deadline. Digital securities fall outside MiCAR's scope but the payment leg does not. To receive, hold, and transfer crypto assets and stablecoins on behalf of clients during subscription and redemption, a platform requires a CASP licence under MiCAR and a PI. Without both, a platform can issue digital securities but cannot move the capital. With MiCAR's transitional period ending on 30 June 2026, a sign
NHOA Energy Awarded Culcairn Battery Contract by Neoen in Australia30.6.2026 09:06:00 CEST | Press release
The landmark Culcairn Battery contract builds on the successful delivery of Neoen’s Blyth Battery by NHOA Energy in Australia, strengthening the long-standing relationship between both companies NHOA Energy, global provider of utility-scale energy storage systems, has been awarded notice-to-proceed by Neoen, one of the world’s leading renewable energy companies, on the latter’s Culcairn Battery, a 215 MW / 963 MWh project to be installed in New South Wales (NSW), Australia. The project will be delivered under an EPC contract in partnership with a joint venture between Equans Solar & Storage and Bouygues Construction Australia and marks a significant new milestone in the long-standing partnership between Neoen and NHOA Energy in Australia. The announcement follows the successful delivery of work by NHOA Energy on Neoen’s 238.5 MW / 477 MWh Blyth Battery in South Australia, in operation since early 2025, and reaffirms NHOA Energy’s leading role in the growth of large-scale energy storage
Manago AI, Formerly SALESmanago, Unveils New Identity and Agentic AI Capabilities to Help Brands Move Faster and Make Powerful Marketing Feel Simple30.6.2026 09:00:00 CEST | Press release
- Manago AI helps brands understand every customer and turn insights into personalised engagement in minutes, dramatically reducing marketing complexity Manago AI today announces the next evolution of its Customer Engagement Platform, combining a new brand identity, agentic AI capabilities, an improved user experience, and a simplified commercial model designed to help growing companies realise value faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630694104/en/ From left: Marcin Stelmach, Director of Customer Success, Klaudia Penkalla, Chief of Staff, Phil Draper, CEO, and Marek Broda, CDFO The launch coincides with the company’s rebrand from SALESmanago, one of the first marketing automation platforms in Europe, to Manago AI. This reflects a broader business transformation focused on helping marketers move faster, reduce complexity and achieve value sooner through AI-powered customer engagement. Designed for eComm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom